JP2003530433A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003530433A5 JP2003530433A5 JP2001576013A JP2001576013A JP2003530433A5 JP 2003530433 A5 JP2003530433 A5 JP 2003530433A5 JP 2001576013 A JP2001576013 A JP 2001576013A JP 2001576013 A JP2001576013 A JP 2001576013A JP 2003530433 A5 JP2003530433 A5 JP 2003530433A5
- Authority
- JP
- Japan
- Prior art keywords
- alkoxy
- sulfamyl
- amino
- acetoxy
- phosphonate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 Hydrogen Chemical class 0.000 description 76
- 125000003545 alkoxy group Chemical group 0.000 description 42
- 229910052736 halogen Inorganic materials 0.000 description 25
- 150000002367 halogens Chemical class 0.000 description 25
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 25
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 24
- 229910052739 hydrogen Inorganic materials 0.000 description 23
- 239000001257 hydrogen Substances 0.000 description 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 22
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 20
- 125000000217 alkyl group Chemical group 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 16
- 150000002431 hydrogen Chemical class 0.000 description 16
- 150000003839 salts Chemical class 0.000 description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 206010016654 Fibrosis Diseases 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- SBSLPPMPINEXNI-YDWXAUTNSA-N 1,2,3,4,5-pentafluoro-6-[(e)-3-(4-fluorophenyl)-1-[(e)-3-(4-fluorophenyl)-1-(2,3,4,5,6-pentafluorophenyl)prop-2-enyl]sulfonylprop-2-enyl]benzene Chemical compound C1=CC(F)=CC=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C=CC(F)=CC=1)C=1C(=C(F)C(F)=C(F)C=1F)F)C1=C(F)C(F)=C(F)C(F)=C1F SBSLPPMPINEXNI-YDWXAUTNSA-N 0.000 description 1
- JYQVQRVNPTWWPZ-WGDLNXRISA-N 1,2,3,4,5-pentafluoro-6-[(e)-3-(4-fluorophenyl)-3-[(e)-1-(4-fluorophenyl)-3-(2,3,4,5,6-pentafluorophenyl)prop-2-enyl]sulfonylprop-1-enyl]benzene Chemical compound C1=CC(F)=CC=C1C(S(=O)(=O)C(\C=C\C=1C(=C(F)C(F)=C(F)C=1F)F)C=1C=CC(F)=CC=1)\C=C\C1=C(F)C(F)=C(F)C(F)=C1F JYQVQRVNPTWWPZ-WGDLNXRISA-N 0.000 description 1
- ZBFGDONTPUMMDC-WGDLNXRISA-N 1,2,3,4,5-pentafluoro-6-[(e)-3-(4-iodophenyl)-3-[(e)-1-(4-iodophenyl)-3-(2,3,4,5,6-pentafluorophenyl)prop-2-enyl]sulfonylprop-1-enyl]benzene Chemical compound FC1=C(F)C(F)=C(F)C(F)=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C(=C(F)C(F)=C(F)C=1F)F)C=1C=CC(I)=CC=1)C1=CC=C(I)C=C1 ZBFGDONTPUMMDC-WGDLNXRISA-N 0.000 description 1
- YFQFBQIGRJQFFS-BGPOSVGRSA-N 1,2,3-trifluoro-4-[(e)-3-(4-fluorophenyl)-3-[(e)-1-(4-fluorophenyl)-3-(2,3,4-trifluorophenyl)prop-2-enyl]sulfonylprop-1-enyl]benzene Chemical compound C1=CC(F)=CC=C1C(S(=O)(=O)C(\C=C\C=1C(=C(F)C(F)=CC=1)F)C=1C=CC(F)=CC=1)\C=C\C1=CC=C(F)C(F)=C1F YFQFBQIGRJQFFS-BGPOSVGRSA-N 0.000 description 1
- PZGCQHVZLVMFTO-FCXRPNKRSA-N 1-[(e)-3-(3,4-dichlorophenyl)-3-[(e)-1-(3,4-dichlorophenyl)-3-(2,3,4,5,6-pentafluorophenyl)prop-2-enyl]sulfonylprop-1-enyl]-2,3,4,5,6-pentafluorobenzene Chemical compound FC1=C(F)C(F)=C(F)C(F)=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C(=C(F)C(F)=C(F)C=1F)F)C=1C=C(Cl)C(Cl)=CC=1)C1=CC=C(Cl)C(Cl)=C1 PZGCQHVZLVMFTO-FCXRPNKRSA-N 0.000 description 1
- YLDNMXSNYYBDFG-YDWXAUTNSA-N 1-[(e)-3-(4-bromophenyl)-1-[(e)-3-(4-bromophenyl)-1-(2,3,4,5,6-pentafluorophenyl)prop-2-enyl]sulfonylprop-2-enyl]-2,3,4,5,6-pentafluorobenzene Chemical compound FC1=C(F)C(F)=C(F)C(F)=C1C(S(=O)(=O)C(\C=C\C=1C=CC(Br)=CC=1)C=1C(=C(F)C(F)=C(F)C=1F)F)\C=C\C1=CC=C(Br)C=C1 YLDNMXSNYYBDFG-YDWXAUTNSA-N 0.000 description 1
- LBRHQENFVSXKJM-YDWXAUTNSA-N 1-[(e)-3-(4-chlorophenyl)-1-[(e)-3-(4-chlorophenyl)-1-(2,3,4,5,6-pentafluorophenyl)prop-2-enyl]sulfonylprop-2-enyl]-2,3,4,5,6-pentafluorobenzene Chemical compound FC1=C(F)C(F)=C(F)C(F)=C1C(S(=O)(=O)C(\C=C\C=1C=CC(Cl)=CC=1)C=1C(=C(F)C(F)=C(F)C=1F)F)\C=C\C1=CC=C(Cl)C=C1 LBRHQENFVSXKJM-YDWXAUTNSA-N 0.000 description 1
- ASWIUWIUYBQFRE-BGPOSVGRSA-N 1-[(e)-3-(4-chlorophenyl)-3-[(e)-1-(4-chlorophenyl)-3-(2,3,4-trifluorophenyl)prop-2-enyl]sulfonylprop-1-enyl]-2,3,4-trifluorobenzene Chemical compound FC1=C(F)C(F)=CC=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C(=C(F)C(F)=CC=1)F)C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 ASWIUWIUYBQFRE-BGPOSVGRSA-N 0.000 description 1
- PBMCWLMEWFGPBX-ZPUQHVIOSA-N 1-[(e)-3-[(e)-1,3-bis(2,3,4,5,6-pentafluorophenyl)prop-2-enyl]sulfonyl-3-(2,3,4,5,6-pentafluorophenyl)prop-1-enyl]-2,3,4,5,6-pentafluorobenzene Chemical compound FC1=C(F)C(F)=C(F)C(F)=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C(=C(F)C(F)=C(F)C=1F)F)C=1C(=C(F)C(F)=C(F)C=1F)F)C1=C(F)C(F)=C(F)C(F)=C1F PBMCWLMEWFGPBX-ZPUQHVIOSA-N 0.000 description 1
- UYBARLRUHOODMT-JYFOCSDGSA-N 1-[(e)-3-[(e)-3-(4,5-dimethoxy-2-nitrophenyl)-1-(4-methoxyphenyl)prop-2-enyl]sulfonyl-3-(4-methoxyphenyl)prop-1-enyl]-4,5-dimethoxy-2-nitrobenzene Chemical compound C1=CC(OC)=CC=C1C(S(=O)(=O)C(\C=C\C=1C(=CC(OC)=C(OC)C=1)[N+]([O-])=O)C=1C=CC(OC)=CC=1)\C=C\C1=CC(OC)=C(OC)C=C1[N+]([O-])=O UYBARLRUHOODMT-JYFOCSDGSA-N 0.000 description 1
- IXKPKFXAOWLGBA-YTEMWHBBSA-N 2-[(e)-3-(4-bromophenyl)-3-[(e)-1-(4-bromophenyl)-3-(2,4,6-trimethoxyphenyl)prop-2-enyl]sulfonylprop-1-enyl]-1,3,5-trimethoxybenzene Chemical compound COC1=CC(OC)=CC(OC)=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C(=CC(OC)=CC=1OC)OC)C=1C=CC(Br)=CC=1)C1=CC=C(Br)C=C1 IXKPKFXAOWLGBA-YTEMWHBBSA-N 0.000 description 1
- GMGWSYNUDNAELW-WXUKJITCSA-N 2-[(e)-3-(4-bromophenyl)-3-[(e)-1-(4-bromophenyl)-3-(4-fluoro-2,6-dimethoxyphenyl)prop-2-enyl]sulfonylprop-1-enyl]-5-fluoro-1,3-dimethoxybenzene Chemical compound COC1=CC(F)=CC(OC)=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C(=CC(F)=CC=1OC)OC)C=1C=CC(Br)=CC=1)C1=CC=C(Br)C=C1 GMGWSYNUDNAELW-WXUKJITCSA-N 0.000 description 1
- PNYMULXLZQBRJS-WXUKJITCSA-N 2-[(e)-3-(4-chlorophenyl)-3-[(e)-1-(4-chlorophenyl)-3-(2-hydroxy-4,6-dimethoxyphenyl)prop-2-enyl]sulfonylprop-1-enyl]-3,5-dimethoxyphenol Chemical compound COC1=CC(OC)=CC(O)=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C(=CC(OC)=CC=1O)OC)C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 PNYMULXLZQBRJS-WXUKJITCSA-N 0.000 description 1
- VHWWYXCXNRDABI-WXUKJITCSA-N 2-[(e)-3-(4-chlorophenyl)-3-[(e)-1-(4-chlorophenyl)-3-(4-fluoro-2,6-dimethoxyphenyl)prop-2-enyl]sulfonylprop-1-enyl]-5-fluoro-1,3-dimethoxybenzene Chemical compound COC1=CC(F)=CC(OC)=C1\C=C\C(S(=O)(=O)C(\C=C\C=1C(=CC(F)=CC=1OC)OC)C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 VHWWYXCXNRDABI-WXUKJITCSA-N 0.000 description 1
- HOPUNXURSBBUQQ-YTEMWHBBSA-N 2-[(e)-3-[(e)-3-(2-hydroxy-4,6-dimethoxyphenyl)-1-(4-methoxyphenyl)prop-2-enyl]sulfonyl-3-(4-methoxyphenyl)prop-1-enyl]-3,5-dimethoxyphenol Chemical compound C1=CC(OC)=CC=C1C(S(=O)(=O)C(\C=C\C=1C(=CC(OC)=CC=1O)OC)C=1C=CC(OC)=CC=1)\C=C\C1=C(O)C=C(OC)C=C1OC HOPUNXURSBBUQQ-YTEMWHBBSA-N 0.000 description 1
- LSQPHWBCMFQPAP-UHFFFAOYSA-N C1=CC(OC)=CC=C1C(S(=O)(=O)C(C=CC=1C(=CC(OC)=CC=1OC)OC)C=1C=CC(OC)=CC=1)C=CC1=C(OC)C=C(OC)C=C1OC Chemical compound C1=CC(OC)=CC=C1C(S(=O)(=O)C(C=CC=1C(=CC(OC)=CC=1OC)OC)C=1C=CC(OC)=CC=1)C=CC1=C(OC)C=C(OC)C=C1OC LSQPHWBCMFQPAP-UHFFFAOYSA-N 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 208000011379 keloid formation Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19784900P | 2000-04-14 | 2000-04-14 | |
| US60/197,849 | 2000-04-14 | ||
| US23470700P | 2000-09-22 | 2000-09-22 | |
| US60/234,707 | 2000-09-22 | ||
| US27164001P | 2001-02-27 | 2001-02-27 | |
| US60/271,640 | 2001-02-27 | ||
| PCT/US2001/012134 WO2001078712A1 (en) | 2000-04-14 | 2001-04-13 | Substituted styryl benzylsulfones for treating proliferative disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003530433A JP2003530433A (ja) | 2003-10-14 |
| JP2003530433A5 true JP2003530433A5 (enExample) | 2008-05-29 |
| JP4677162B2 JP4677162B2 (ja) | 2011-04-27 |
Family
ID=27393791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001576013A Expired - Lifetime JP4677162B2 (ja) | 2000-04-14 | 2001-04-13 | 増殖性障害を治療するための置換スチリルベンジルスルホン |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6486210B2 (enExample) |
| EP (2) | EP1305015B1 (enExample) |
| JP (1) | JP4677162B2 (enExample) |
| KR (1) | KR100768415B1 (enExample) |
| AU (2) | AU2001251615C1 (enExample) |
| CA (1) | CA2406212C (enExample) |
| DK (1) | DK1305015T3 (enExample) |
| ES (1) | ES2427088T3 (enExample) |
| IL (2) | IL152190A0 (enExample) |
| NZ (1) | NZ522551A (enExample) |
| PT (1) | PT1305015E (enExample) |
| SI (1) | SI1305015T1 (enExample) |
| WO (1) | WO2001078712A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6762207B1 (en) * | 1999-04-02 | 2004-07-13 | Temple University - Of The Commonwealth System Of Higher Education | (E)-styryl sulfone anticancer agents |
| CA2424884C (en) | 2000-10-05 | 2009-12-15 | E. Premkumar Reddy | Substituted (e)-styryl benzylsulfones for treating proliferative disorders |
| WO2002067913A1 (en) * | 2001-02-27 | 2002-09-06 | Temple University-Of The Commonwealth System Of Higher Education | (z)-styrylbenzylsulfones and pharmaceutical uses thereof |
| US6667346B2 (en) | 2001-02-28 | 2003-12-23 | Temple University - Of The Commonwealth System Of Higher Education | Method for protecting cells and tissues from ionizing radiation toxicity with α, β unsaturated aryl sulfones |
| NZ535232A (en) * | 2002-02-28 | 2007-05-31 | Univ Temple | Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders |
| IL163608A0 (en) * | 2002-02-28 | 2005-12-18 | Univ Temple | Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders |
| JP4182844B2 (ja) * | 2003-09-03 | 2008-11-19 | 株式会社島津製作所 | 質量分析装置 |
| AU2004289281C1 (en) * | 2003-11-14 | 2011-12-08 | Onconova Therapeutics, Inc. | Alpha, beta-Unsaturated sulfoxides for treating proliferative disorders |
| AU2005222947B2 (en) * | 2004-03-16 | 2010-12-23 | Onconova Therapeutics Inc. | Substituted phenoxy- and phenylthio- derivatives for treating proliferative disorders |
| US8058313B2 (en) | 2004-06-24 | 2011-11-15 | Temple University—Of the Commonwealth System of Higher Education | Alpha, beta-unsaturated sulfones, sulfoxides, sulfonimides, sulfinimides, acylsulfonamides and acylsulfinamides and therapeutic uses thereof |
| US20090306207A1 (en) * | 2005-01-05 | 2009-12-10 | Reddy M V Ramana | Treatment of Drug-Resistant Proliferative Disorders |
| US8143453B2 (en) * | 2005-02-25 | 2012-03-27 | Temple University—Of the Commonwealth System of Higher Education | Unsaturated sulfides, sulfones, sulfoxides and sulfonamides synthesis |
| WO2006104668A2 (en) * | 2005-03-11 | 2006-10-05 | Temple University - Of The Commonwealth System Of Higher Education | Composition and methods for the treatment of proliferative diseases |
| US8664272B2 (en) | 2006-08-30 | 2014-03-04 | Temple University—Of the Commonwealth System of Higher Education | Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia |
| CA2663375A1 (en) * | 2006-09-15 | 2008-03-20 | Onconova Therapeutics, Inc. | Activated cytotoxic compounds for attachment to targeting molecules for the treatment of mammalian disease conditions |
| US8735620B2 (en) * | 2008-12-17 | 2014-05-27 | Epr Pharmaceuticals Pvt. Ltd | Processes for preparing (E)-styrylbenzylsulfone compounds and uses thereof for treating proliferative disorders |
| CA2885217C (en) | 2012-09-20 | 2019-10-08 | Temple University - Of The Commonwealth System Of Higher Education | Substituted alkyl diaryl derivatives, methods of preparation and uses |
| ES2864681T3 (es) | 2012-12-07 | 2021-10-14 | Onconova Therapeutics Inc | Tratamiento del cáncer hematológico refractario a un agente contra el cáncer |
| US10383831B2 (en) | 2015-08-03 | 2019-08-20 | Temple University—Of the Commonwealth System of Higher Education | 2,4,6-trialkoxystryl aryl sulfones, sulfonamides and carboxamides, and methods of preparation and use |
| WO2024186641A1 (en) * | 2023-03-03 | 2024-09-12 | Onconova Therapeutics, Inc. | Methods and compositions for treating cancer |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2532612A (en) | 1945-08-29 | 1950-12-05 | Union Oil Co | Preparation of unsaturated thio-ethers |
| US3185743A (en) | 1960-08-24 | 1965-05-25 | Union Carbide Corp | Production of olefinic compounds from allyl sulfones |
| US3418101A (en) | 1965-12-15 | 1968-12-24 | Pennsalt Chemicals Corp | Process for plant desiccation |
| US3514386A (en) | 1967-12-11 | 1970-05-26 | Exxon Research Engineering Co | Stereoselective addition of thiols to acetylenic compounds |
| US3917714A (en) | 1972-09-06 | 1975-11-04 | American Cyanamid Co | Bis(alkylsulfonyl)vinylbenzenes |
| US4161407A (en) | 1977-10-06 | 1979-07-17 | Eastman Kodak Company | Crosslinkable polymers having vinylsulfonyl groups or styrylsulfonyl groups and their use as hardeners for gelatin |
| US4386221A (en) | 1981-10-28 | 1983-05-31 | Eastman Kodak Company | Process for the preparation of aryl alkyl sulfones and aryl vinyl sulfones |
| US4937388A (en) | 1985-08-09 | 1990-06-26 | Imperial Chemical Industries Plc | Insecticidal ethers |
| YU213587A (en) * | 1986-11-28 | 1989-06-30 | Orion Yhtymae Oy | Process for obtaining new pharmacologic active cateholic derivatives |
| FR2621038B1 (fr) * | 1987-09-28 | 1989-12-29 | Rhone Poulenc Sante | Derives d'alcadienes, leurs preparations, les medicaments les contenant et produits intermediaires |
| GB8902409D0 (en) * | 1989-02-03 | 1989-03-22 | Ici Plc | Aliphatic compounds |
| US5659087A (en) | 1995-06-07 | 1997-08-19 | Eli Lilly And Company | Diarylvinyl sulfoxides |
| JP3660395B2 (ja) * | 1995-06-22 | 2005-06-15 | 大鵬薬品工業株式会社 | フェニルスルホン誘導体及びその製造方法 |
| EP0855998B1 (en) * | 1995-10-19 | 2001-01-10 | Ciba Specialty Chemicals Holding Inc. | Antioxidants containing phenol groups and aromatic amine groups |
| ATE284386T1 (de) | 1997-10-03 | 2004-12-15 | Univ Temple | Styrolsulfone als antikrebsmittel |
| US6201154B1 (en) * | 1999-03-31 | 2001-03-13 | Temple University-Of The Commonwealth Of Higher Education | Z-styryl sulfone anticancer agents |
| WO2000059494A1 (en) * | 1999-04-02 | 2000-10-12 | Temple University- Of The Commonwealth System Of Higher Education | Styryl sulfone anticancer agents |
| WO2000059495A1 (en) * | 1999-04-02 | 2000-10-12 | Temple University - Of The Commonwealth System Of Higher Education | (e)-styryl sulfone anticancer agents |
| IL149064A0 (en) * | 1999-10-12 | 2002-11-10 | Univ Temple | Method for protecting normal cells from cytotoxicity of chemotherapeutic agents |
-
2001
- 2001-04-12 US US09/833,287 patent/US6486210B2/en not_active Expired - Lifetime
- 2001-04-13 WO PCT/US2001/012134 patent/WO2001078712A1/en not_active Ceased
- 2001-04-13 NZ NZ522551A patent/NZ522551A/en not_active IP Right Cessation
- 2001-04-13 PT PT1925014T patent/PT1305015E/pt unknown
- 2001-04-13 KR KR1020027013708A patent/KR100768415B1/ko not_active Expired - Lifetime
- 2001-04-13 EP EP01925014.1A patent/EP1305015B1/en not_active Expired - Lifetime
- 2001-04-13 SI SI200131022T patent/SI1305015T1/sl unknown
- 2001-04-13 DK DK01925014.1T patent/DK1305015T3/da active
- 2001-04-13 IL IL15219001A patent/IL152190A0/xx unknown
- 2001-04-13 AU AU2001251615A patent/AU2001251615C1/en not_active Expired
- 2001-04-13 JP JP2001576013A patent/JP4677162B2/ja not_active Expired - Lifetime
- 2001-04-13 EP EP10178360A patent/EP2359819A1/en not_active Withdrawn
- 2001-04-13 AU AU5161501A patent/AU5161501A/xx active Pending
- 2001-04-13 ES ES01925014T patent/ES2427088T3/es not_active Expired - Lifetime
- 2001-04-13 CA CA2406212A patent/CA2406212C/en not_active Expired - Lifetime
-
2002
- 2002-07-29 US US10/207,429 patent/US6642410B2/en not_active Expired - Lifetime
- 2002-10-08 IL IL152190A patent/IL152190A/en active IP Right Grant